Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global CINV Existing and Pipeline Drugs market is projected to grow from US$ 1618.3 million in 2023 to US$ 1954.9 million by 2029, at a Compound Annual Growth Rate (CAGR) of 3.2% during the forecast period.
The US & Canada market for CINV Existing and Pipeline Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for CINV Existing and Pipeline Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for CINV Existing and Pipeline Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key manufacturers of CINV Existing and Pipeline Drugs include GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck and Tesaro, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes:
This report presents an overview of global market for CINV Existing and Pipeline Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of CINV Existing and Pipeline Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for CINV Existing and Pipeline Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the CINV Existing and Pipeline Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global CINV Existing and Pipeline Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for CINV Existing and Pipeline Drugs sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck and Tesaro, etc.
By Company
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Segment by Type
Aloxi
Zofran Generic
Kytril Generic
Emend
Akynzeo
SUSTOL
Rolapitant
Segment by Application
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of CINV Existing and Pipeline Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of CINV Existing and Pipeline Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: China by type, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CINV Existing and Pipeline Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 CINV Existing and Pipeline Drugs Product Introduction
1.2 Market by Type
1.2.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Aloxi
1.2.3 Zofran Generic
1.2.4 Kytril Generic
1.2.5 Emend
1.2.6 Akynzeo
1.2.7 SUSTOL
1.2.8 Rolapitant
1.3 Market by Application
1.3.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Diagnostic Centers Therapeutics
1.3.5 Hospital Pharmacies
1.3.6 Drugstores
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global CINV Existing and Pipeline Drugs Sales Estimates and Forecasts 2018-2029
2.2 Global CINV Existing and Pipeline Drugs Revenue by Region
2.2.1 Global CINV Existing and Pipeline Drugs Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global CINV Existing and Pipeline Drugs Revenue by Region (2018-2023)
2.2.3 Global CINV Existing and Pipeline Drugs Revenue by Region (2024-2029)
2.2.4 Global CINV Existing and Pipeline Drugs Revenue Market Share by Region (2018-2029)
2.3 Global CINV Existing and Pipeline Drugs Sales Estimates and Forecasts 2018-2029
2.4 Global CINV Existing and Pipeline Drugs Sales by Region
2.4.1 Global CINV Existing and Pipeline Drugs Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global CINV Existing and Pipeline Drugs Sales by Region (2018-2023)
2.4.3 Global CINV Existing and Pipeline Drugs Sales by Region (2024-2029)
2.4.4 Global CINV Existing and Pipeline Drugs Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global CINV Existing and Pipeline Drugs Sales by Manufacturers
3.1.1 Global CINV Existing and Pipeline Drugs Sales by Manufacturers (2018-2023)
3.1.2 Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of CINV Existing and Pipeline Drugs in 2022
3.2 Global CINV Existing and Pipeline Drugs Revenue by Manufacturers
3.2.1 Global CINV Existing and Pipeline Drugs Revenue by Manufacturers (2018-2023)
3.2.2 Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by CINV Existing and Pipeline Drugs Revenue in 2022
3.3 Global Key Players of CINV Existing and Pipeline Drugs, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global CINV Existing and Pipeline Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Product Offered and Application
3.8 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global CINV Existing and Pipeline Drugs Sales by Type
4.1.1 Global CINV Existing and Pipeline Drugs Historical Sales by Type (2018-2023)
4.1.2 Global CINV Existing and Pipeline Drugs Forecasted Sales by Type (2024-2029)
4.1.3 Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2018-2029)
4.2 Global CINV Existing and Pipeline Drugs Revenue by Type
4.2.1 Global CINV Existing and Pipeline Drugs Historical Revenue by Type (2018-2023)
4.2.2 Global CINV Existing and Pipeline Drugs Forecasted Revenue by Type (2024-2029)
4.2.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2018-2029)
4.3 Global CINV Existing and Pipeline Drugs Price by Type
4.3.1 Global CINV Existing and Pipeline Drugs Price by Type (2018-2023)
4.3.2 Global CINV Existing and Pipeline Drugs Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global CINV Existing and Pipeline Drugs Sales by Application
5.1.1 Global CINV Existing and Pipeline Drugs Historical Sales by Application (2018-2023)
5.1.2 Global CINV Existing and Pipeline Drugs Forecasted Sales by Application (2024-2029)
5.1.3 Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2018-2029)
5.2 Global CINV Existing and Pipeline Drugs Revenue by Application
5.2.1 Global CINV Existing and Pipeline Drugs Historical Revenue by Application (2018-2023)
5.2.2 Global CINV Existing and Pipeline Drugs Forecasted Revenue by Application (2024-2029)
5.2.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2018-2029)
5.3 Global CINV Existing and Pipeline Drugs Price by Application
5.3.1 Global CINV Existing and Pipeline Drugs Price by Application (2018-2023)
5.3.2 Global CINV Existing and Pipeline Drugs Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada CINV Existing and Pipeline Drugs Market Size by Type
6.1.1 US & Canada CINV Existing and Pipeline Drugs Sales by Type (2018-2029)
6.1.2 US & Canada CINV Existing and Pipeline Drugs Revenue by Type (2018-2029)
6.2 US & Canada CINV Existing and Pipeline Drugs Market Size by Application
6.2.1 US & Canada CINV Existing and Pipeline Drugs Sales by Application (2018-2029)
6.2.2 US & Canada CINV Existing and Pipeline Drugs Revenue by Application (2018-2029)
6.3 US & Canada CINV Existing and Pipeline Drugs Market Size by Country
6.3.1 US & Canada CINV Existing and Pipeline Drugs Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada CINV Existing and Pipeline Drugs Sales by Country (2018-2029)
6.3.3 US & Canada CINV Existing and Pipeline Drugs Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe CINV Existing and Pipeline Drugs Market Size by Type
7.1.1 Europe CINV Existing and Pipeline Drugs Sales by Type (2018-2029)
7.1.2 Europe CINV Existing and Pipeline Drugs Revenue by Type (2018-2029)
7.2 Europe CINV Existing and Pipeline Drugs Market Size by Application
7.2.1 Europe CINV Existing and Pipeline Drugs Sales by Application (2018-2029)
7.2.2 Europe CINV Existing and Pipeline Drugs Revenue by Application (2018-2029)
7.3 Europe CINV Existing and Pipeline Drugs Market Size by Country
7.3.1 Europe CINV Existing and Pipeline Drugs Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe CINV Existing and Pipeline Drugs Sales by Country (2018-2029)
7.3.3 Europe CINV Existing and Pipeline Drugs Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China CINV Existing and Pipeline Drugs Market Size
8.1.1 China CINV Existing and Pipeline Drugs Sales (2018-2029)
8.1.2 China CINV Existing and Pipeline Drugs Revenue (2018-2029)
8.2 China CINV Existing and Pipeline Drugs Market Size by Application
8.2.1 China CINV Existing and Pipeline Drugs Sales by Application (2018-2029)
8.2.2 China CINV Existing and Pipeline Drugs Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia CINV Existing and Pipeline Drugs Market Size by Type
9.1.1 Asia CINV Existing and Pipeline Drugs Sales by Type (2018-2029)
9.1.2 Asia CINV Existing and Pipeline Drugs Revenue by Type (2018-2029)
9.2 Asia CINV Existing and Pipeline Drugs Market Size by Application
9.2.1 Asia CINV Existing and Pipeline Drugs Sales by Application (2018-2029)
9.2.2 Asia CINV Existing and Pipeline Drugs Revenue by Application (2018-2029)
9.3 Asia CINV Existing and Pipeline Drugs Sales by Region
9.3.1 Asia CINV Existing and Pipeline Drugs Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia CINV Existing and Pipeline Drugs Revenue by Region (2018-2029)
9.3.3 Asia CINV Existing and Pipeline Drugs Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Market Size by Type
10.1.1 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Market Size by Application
10.2.1 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America CINV Existing and Pipeline Drugs Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Information
11.1.2 GlaxoSmithKline Overview
11.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 GlaxoSmithKline Recent Developments
11.2 Helsinn
11.2.1 Helsinn Company Information
11.2.2 Helsinn Overview
11.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Helsinn CINV Existing and Pipeline Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Helsinn Recent Developments
11.3 Heron Therapeutics
11.3.1 Heron Therapeutics Company Information
11.3.2 Heron Therapeutics Overview
11.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Heron Therapeutics Recent Developments
11.4 Merck
11.4.1 Merck Company Information
11.4.2 Merck Overview
11.4.3 Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Merck CINV Existing and Pipeline Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merck Recent Developments
11.5 Tesaro
11.5.1 Tesaro Company Information
11.5.2 Tesaro Overview
11.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Tesaro CINV Existing and Pipeline Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Tesaro Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 CINV Existing and Pipeline Drugs Industry Chain Analysis
12.2 CINV Existing and Pipeline Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 CINV Existing and Pipeline Drugs Production Mode & Process
12.4 CINV Existing and Pipeline Drugs Sales and Marketing
12.4.1 CINV Existing and Pipeline Drugs Sales Channels
12.4.2 CINV Existing and Pipeline Drugs Distributors
12.5 CINV Existing and Pipeline Drugs Customers
13 Market Dynamics
13.1 CINV Existing and Pipeline Drugs Industry Trends
13.2 CINV Existing and Pipeline Drugs Market Drivers
13.3 CINV Existing and Pipeline Drugs Market Challenges
13.4 CINV Existing and Pipeline Drugs Market Restraints
14 Key Findings in The Global CINV Existing and Pipeline Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
听
听
*If Applicable.